Partner Headlines - AMGN

  1. Morgan Stanley Issues 2015 'Vintage Values' Stock List

    Benzinga
  2. Celgene Drug Otezla Fails Trial, But Street Sanguine

    IBD
  3. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  4. Bind Therapeutics

    IBD
  5. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  6. Bind Therapeutics Down After Losing Amgen Partnership

    IBD
  7. Dow Hits 17,000 On Jobs Report; Walgreen Same-Store-Sales Surge ...

    Benzinga
  8. Morning Market Losers

    Benzinga
  9. Top 4 Stocks In The Biotechnology Industry With The Highest EPS

    Benzinga
  10. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  11. InterMune Up On Bullish View Of U.S. Esbriet Launch

    IBD
  12. UPDATE: Morgan Stanley Reiterates On Amgen On New CFO

    Benzinga
  13. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  14. UPDATE: Morgan Stanley Reiterates On Amgen Following AMAGINE-1 ...

    Benzinga
  15. Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and ...

    GuruFocus
  16. Amgen

    IBD
  17. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest ...

    Benzinga
  18. Amgen Blazed Biotech Trail, Earned 165,233% Reward

    IBD
  19. Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple ...

    Benzinga
  20. Stocks End Six-Day Win Streak As Techs Sell Off

    IBD
  21. Stock Futures Mixed And Busy; Illumina Rockets, Cree Tumbles

    IBD
  22. #PreMarket Primer: Wednesday, April 23: Data From China Takes ...

    Benzinga
  23. AMGEN

    IBD
  24. Gilead Soars As Hep C Drug Shatters Views; Amgen Misses

    IBD
  25. Rallying Ahead of Earnings

    FoxBusiness
  26. Nasdaq, S&P 500 On Track For Sixth Straight Gain

    IBD
  27. Amgen Slumps After 1Q Earnings Miss

    FoxBusiness
  28. Stocks Power Out Early Gains; Allergan Leads Drug-Maker Surge

    IBD
  29. Earnings Scheduled For April 22, 2014

    Benzinga
  30. Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

    IBD
  31. Short Interest Rises As Biotechs Fall (AMGN, CELG, DNDN)

    Benzinga
  32. Pfizer Breast-Cancer Drug Scores, But Street Cautious

    IBD
  33. UPDATE: Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable ...

    Benzinga
  34. Amgen, GSK End Marketing Pact for Osteoporosis Drug

    FoxBusiness
  35. Cholesterol drug meets goal

    IBD
  36. Trial Results Lift Drug Sector

    IBD
  37. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  38. Jefferies Raises PT On Amgen, Pricing Pressure Factored IN

    Benzinga
  39. Gilead Adds To Biotech Woes

    IBD
  40. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  41. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  42. Market Wrap For March 27: Markets Lower Following Mixed Economic ...

    Benzinga
  43. Biotech ETFs Come Back Down To Earth

    Benzinga
  44. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  45. BIOGEN IDEC

    IBD
  46. Have We Seen The Top Of The Market?

    Benzinga
  47. Market Wrap For March 18: Markets Positive Despite Crimea Concerns

    Benzinga
  48. Amgen up on drug trial result

    IBD
  49. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  50. US Stock Futures Edge Lower Ahead Of Wholesale Trade Data

    Benzinga
  51. Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results ...

    Benzinga
  52. Regeneron Cholesterol-Drug Worries Ding Stock

    IBD
  53. Biogen Idec Keeps Momentum Going With MS Drug Tecfidera

    IBD
  54. Insys Set To Report Q4 Earnings With Stock Surging

    IBD
  55. Why Stock Shakeouts Can Be Scary, Yet Constructive

    IBD
  56. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  57. Novartis Vs. Everyone: Biologic Knockoffs

    YCharts
  58. Revenue Growth: Focus On Healthcare Stocks

    YCharts
  59. France's Biosimilar Substitution May Lead to Erosion of Amgen

    Benzinga
  60. Why Mr. Cautious Is 82% Invested In Stocks

    YCharts
  61. Illumina, Alexion Lead 4 Big Caps Drawing Big Buyers

    IBD
  62. You Can No Longer Ignore Biotech

    GuruFocus
  63. Merck soars on cancer deal

    IBD
  64. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD
  65. Merck Misses Estimates in 4Q; Plans Increased Focus on Cancer

    FoxBusiness
  66. Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 ...

    Benzinga
  67. Pfizer, Amgen Earnings Beat

    IBD
  68. Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 ...

    Benzinga
  69. Earnings Scheduled For January 28, 2014

    Benzinga
  70. Benzinga Weekly Preview: Tech Sector To Steal The Spotlight

    Benzinga
  71. Amgen

    IBD
  72. Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-2 ...

    Benzinga
  73. Drugmaker Merck Tries To Jump-Start Slow Growth

    IBD
  74. Illumina, Jazz Among 5 Young Guns Hitting New Highs

    IBD
  75. Illumina Details Its Strategy; Stock Jumps Again

    IBD
  76. Market Wrap For January 16: Markets End Two Day Winning Streak

    Benzinga
  77. ILLUMINA

    IBD
  78. Drug Buyouts On The Rise -- But Buyers Changing

    IBD
  79. Amgen, Mass General, Broad Institute Collaborate on New Drugs ...

    Benzinga
  80. Biotech Stocks Back On Top, Led By Biogen, Alexion

    IBD
  81. Mario Gabelli Comments on Amgen Inc.

    GuruFocus
  82. Amgen drug gets high marks

    IBD
  83. Amgen Announces Romosozumab Phase 2 Data Published In NEJM Show ...

    Benzinga
  84. Biologic Makers Thwart Generics: Winning Stocks

    YCharts
  85. Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, ...

    Benzinga
  86. 38 Stocks with Higher Dividends

    GuruFocus
  87. Co-Pays: Skin In the Game If It Ain’t Your Skin?

    YCharts
  88. UPDATE: Citigroup Reiterates on Amgen Following Detailed Market ...

    Benzinga
  89. After Top-Seller Remicade: Analysis of J&J’s Future

    YCharts
  90. Goldman Sachs Comments on How Strong Sales of Kyprolis, Epogen, ...

    Benzinga
  91. UPDATE: Piper Jaffray Initiates Coverage on Amgen on Expected ...

    Benzinga
  92. UPDATE: Piper Jaffray Initiates On Amgen On Series Of Bold Steps

    Benzinga
  93. Celgene's Kyprolis Draws Focus Away From Amgen

    Benzinga
  94. J&J’s Top Drug vs. Generic: Investment Thesis

    YCharts
  95. UPDATE: Deutsche Bank Reiterates on Amgen Following Biosimilar ...

    Benzinga
  96. New Statin Rules: Which Drugmakers Had Ties?

    YCharts
  97. Celgene’s Revlimid: Sales to $8B? Patent to 2023?

    YCharts
  98. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  99. Ligand Pharmaceuticals On Pace For Annual Profit

    IBD
  100. Vanguard Health Care Fund's Top Third Quarter Holdings

    GuruFocus
Trading Center